LEXX Lexaria Bioscience Corp.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1348362 · Fiscal year ends 08/31
Financial factors as of 2026-05-31 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-68.5%
TTM net income YoY32.1%
TTM EPS YoY50.0%
Revenue 3-yr CAGR-14.2%
Net income 3-yr CAGR—
Margins
Gross margin100.0%
Operating margin-3,973.2%
Net margin-3,985.6%
FCF margin-3,848.6%
EBITDA margin-3,960.4%
Returns
ROE-150.3%
ROA-134.2%
ROIC (approx.)-553.9%
Asset turnover0.03x
Leverage & solvency
Liabilities / assets9.1%
Debt / equity0.00x
Current ratio10.60x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.96x
Accruals ratio-5.3%
Payout ratio—
Capex / revenue21.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-08-31 | FY20242024-08-31 | FY20232023-08-31 | FY20222022-08-31 | FY20212021-08-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $705,923 | $464,278 | $226,208 | $255,397 | $722,738 |
| Cost of revenue | $2,720 | $4,822 | $31,500 | $71,841 | $175,346 |
| Gross profit | $703,203 | $459,456 | $194,708 | $183,556 | $547,392 |
| R&D expense | $8.24M | $2.36M | $3.67M | $1.84M | $1.26M |
| SG&A expense | $4.35M | $3.85M | $3.06M | $4.96M | $4.97M |
| Operating income | -$11.88M | -$5.75M | -$6.53M | -$6.62M | -$5.69M |
| Interest expense | — | $7,760 | $0 | — | — |
| Pretax income | -$11.91M | -$5.81M | -$6.71M | -$7.38M | -$4.17M |
| Income tax | — | — | — | $0 | $6,093 |
| Net income | -$11.90M | -$5.80M | -$6.66M | -$7.27M | -$4.03M |
| EBITDA | -$11.83M | -$5.71M | -$6.39M | -$6.52M | -$5.58M |
| EPS (basic) | — | — | — | — | -0.95 |
| EPS (diluted) | -0.66 | -0.47 | -1.01 | — | -0.95 |
| Weighted avg. shares (diluted) | 18.00M | 12.38M | 6.61M | — | 4.39M |
| Banking | |||||
| Net interest income | — | $14,311 | $43,190 | — | — |
| Noninterest income | — | — | $43,190 | $0 | — |
| Balance sheet | |||||
| Cash & equivalents | $1.80M | $6.50M | $1.35M | $5.81M | $10.92M |
| Short-term investments | $143,267 | $55,807 | $125,642 | $347,335 | $833,841 |
| Receivables | $368,358 | $154,477 | $126,686 | $201,784 | $342,401 |
| Inventory | — | — | $0 | $38,418 | $29,648 |
| Current assets | $3.47M | $7.90M | $2.15M | $6.98M | $12.44M |
| PP&E, net | $228,129 | $254,709 | $254,143 | $315,505 | $368,213 |
| Intangibles | $307,818 | $516,676 | $462,625 | — | — |
| Total assets | $4.18M | $8.87M | $3.08M | $7.83M | $13.27M |
| Current liabilities | $1.49M | $1.10M | $267,735 | $194,036 | $153,276 |
| Total liabilities | $1.57M | $1.21M | $403,908 | $201,437 | $203,265 |
| Shareholders' equity | $2.99M | $8.04M | $3.04M | $7.95M | $13.06M |
| Shares outstanding | 19.56M | 19.56M | 8.09M | 5.95M | 5.73M |
| Cash flow statement | |||||
| Operating cash flow | -$10.45M | -$4.96M | -$5.88M | -$4.88M | -$3.99M |
| Capital expenditure | $24,646 | $43,014 | $33,748 | $49,192 | — |
| Free cash flow | -$10.48M | -$5.00M | -$5.91M | -$4.93M | — |
| Investing cash flow | -$243,019 | -$188,605 | -$169,610 | -$180,640 | $193,880 |
| Financing cash flow | $6.05M | $10.32M | $1.59M | -$44,600 | $13.42M |
| Depreciation & amortization | $51,225 | $42,448 | $145,397 | $102,718 | $111,718 |
| Stock-based compensation | $859,494 | $492,236 | $170,382 | $752,591 | $410,007 |
Free plan shows the latest 5 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.